While numerous susceptibility loci for epithelial ovarian cancer (EOC) have been identified, few associations have been reported with overall survival. In the absence of common prognostic genetic markers, we hypothesize that rare coding variants may be associated with overall EOC survival and assessed their contribution in two exome-based genotyping projects of the Ovarian Cancer Association Consortium (OCAC). METHODS: The primary patient set (Set 1) included 14 independent EOC studies (4,293 patients) and 227,892 variants, and a secondary patient set (Set 2) included six additional EOC studies (1,744 patients) and 114,620 variants. Because power to detect rare variants individually is reduced, gene-level tests were conducted. Sets were ana...
Epithelial ovarian cancer (EOC) is a heterogeneous cancer with both genetic and environmental risk f...
Epithelial ovarian cancer (EOC) is a heterogeneous cancer with both genetic and environmental risk f...
PURPOSE: Chemotherapy resistance remains a major challenge in the treatment of ovarian cancer. We hy...
BackgroundWhile numerous susceptibility loci for epithelial ovarian cancer (EOC) have been identifie...
BACKGROUND: While numerous susceptibility loci for epithelial ovarian cancer (EOC) have been identif...
BACKGROUND: Genome-wide association studies have identified several common susceptibility alleles fo...
Rare and low frequency variants are not well covered in most germline genotyping arrays and are unde...
Rare and low frequency variants are not well covered in most germline genotyping arrays and are unde...
Genome-wide association studies (GWAS) have identified 12 epithelial ovarian cancer (EOC) susceptibi...
Genome-wide association studies (GWAS) have identified 12 epithelial ovarian cancer (EOC) susceptibi...
Epithelial ovarian cancer (EOC) is a heterogeneous cancer with both genetic and environmental risk f...
Epithelial ovarian cancer (EOC) is a heterogeneous cancer with both genetic and environmental risk f...
Epithelial ovarian cancer (EOC) is a heterogeneous cancer with both genetic and environmental risk f...
Epithelial ovarian cancer (EOC) is a heterogeneous cancer with both genetic and environmental risk f...
Epithelial ovarian cancer (EOC) is a heterogeneous cancer with both genetic and environmental risk f...
Epithelial ovarian cancer (EOC) is a heterogeneous cancer with both genetic and environmental risk f...
Epithelial ovarian cancer (EOC) is a heterogeneous cancer with both genetic and environmental risk f...
PURPOSE: Chemotherapy resistance remains a major challenge in the treatment of ovarian cancer. We hy...
BackgroundWhile numerous susceptibility loci for epithelial ovarian cancer (EOC) have been identifie...
BACKGROUND: While numerous susceptibility loci for epithelial ovarian cancer (EOC) have been identif...
BACKGROUND: Genome-wide association studies have identified several common susceptibility alleles fo...
Rare and low frequency variants are not well covered in most germline genotyping arrays and are unde...
Rare and low frequency variants are not well covered in most germline genotyping arrays and are unde...
Genome-wide association studies (GWAS) have identified 12 epithelial ovarian cancer (EOC) susceptibi...
Genome-wide association studies (GWAS) have identified 12 epithelial ovarian cancer (EOC) susceptibi...
Epithelial ovarian cancer (EOC) is a heterogeneous cancer with both genetic and environmental risk f...
Epithelial ovarian cancer (EOC) is a heterogeneous cancer with both genetic and environmental risk f...
Epithelial ovarian cancer (EOC) is a heterogeneous cancer with both genetic and environmental risk f...
Epithelial ovarian cancer (EOC) is a heterogeneous cancer with both genetic and environmental risk f...
Epithelial ovarian cancer (EOC) is a heterogeneous cancer with both genetic and environmental risk f...
Epithelial ovarian cancer (EOC) is a heterogeneous cancer with both genetic and environmental risk f...
Epithelial ovarian cancer (EOC) is a heterogeneous cancer with both genetic and environmental risk f...
PURPOSE: Chemotherapy resistance remains a major challenge in the treatment of ovarian cancer. We hy...